Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4332

Sort by

Sort Order Select

Journal Articles

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Blood (2019) 134 (23): 2036–2045.

https://doi.org/10.1182/blood.2019000069

Published: 2019

Includes: Supplemental data

Journal Articles

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Dhruv Chopra, MS, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5378.

https://doi.org/10.1182/blood-2019-131028

Published: 2019

Journal Articles

On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study

Olga V. Lazareva, PhD, Ekaterina Yu. Chelysheva, MD PhD, Anton Kulikovsky, Olga Senderova, Valentina Pepeliaeva, Sergey Meresiy, Alexander S. Luchinin, MD, Galina Milutina, Lubov Gavrilova, Ludmila Avdeeva, Dolgorzhap Dasheeva, Olga Vinogradova, MD PhD, Sergei M. Kulikov, PhD, Anna G. Turkina, Prof., MD

Blood (2019) 134 (Supplement_1): 5902.

https://doi.org/10.1182/blood-2019-131430

Published: 2019

Journal Articles

Vaccination with Live Attenuated Virus Vaccines in Four Pediatric Patients with CML While on Imatinib Treatment

Claudia Bettoni Da Cunha-Riehm, MD, Verena Hildebrand, MD, Michaela Nathrath, MD PhD, Markus Metzler, MD PhD, Meinolf Suttorp, MD PhD

Blood (2019) 134 (Supplement_1): 5903.

https://doi.org/10.1182/blood-2019-122219

Published: 2019

Journal Articles

Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 Mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response with Imatinib (PonaZero_study)

Valentin Garcia Gutierrez, MD PhD, Luis Felipe Casado, Rosa Ayala, MD PhD, Fermin Sanchez-Guijo, MD PhD, Juan Carlos Hernandez Boluda, María Teresa Gomez Casares, Blanca Xicoy, MD MSc, Begonya Maestro, PhD, Juan Luis Steegmann, Arturo Garcia de Diego

Blood (2019) 134 (Supplement_1): 5904.

https://doi.org/10.1182/blood-2019-125627

Published: 2019

Journal Articles

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Eva Koriťáková, RNDr., PhD, Michael Doubek, MD PhD, Edgar Faber, MD PhD, Daniela Žáčková, MD PhD, Jan M. Horáček, MD PhD, Petra Bělohlávková, MD PhD, Eduard Cmunt, MD PhD, František Folber, MD PhD, Pavel Jindra, MD PhD, Hana Klamová, MD PhD, Zdeněk Kořístek, MD PhD, Lukáš Stejskal, MD, Tomáš Szotkowski, MD PhD, Cyril Šálek, MD PhD, Renata Kellnerová, MD PhD, Marika Chrápavá, Mgr.

Blood (2019) 134 (Supplement_1): 5905.

https://doi.org/10.1182/blood-2019-126395

Published: 2019

Journal Articles

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Veronica A Guerra, MD, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Srdan Verstovsek, MD PhD, Allison Pike, RN, Farhad Ravandi, MD, Elias Jabbour, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 5906.

https://doi.org/10.1182/blood-2019-127272

Published: 2019

Journal Articles

Effects of Ramadan Fasting in Patients with Chronic Myeloid Leukemia in Chronic Phase

Mohamed A Yassin, MBBS, MSc, Rola S Ghasoub, BSC, Mahmood B Aldapt, MD, Mohammad Abdul-Jaber Abdulla, MD, Prem Chandra, PhD, Hawraa M Shwaylia, MD, Abdulqadir Jeprel Nashwan, BSN, MSN, Nancy Kassem, BSC, Susanna Jane Akiki, PhD

Blood (2019) 134 (Supplement_1): 5907.

https://doi.org/10.1182/blood-2019-121827

Published: 2019

Journal Articles

Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML

Agnès Guerci, MD PhD, Emilie Cayssials, MD, Philippe Rousselot, MD PhD, Francoise Huguet, MD, Valerie Coiteux, MD, Marc G. Berger, MD PhD, Gabriel Etienne, MD PhD, Ali G Turhan, MD PhD

Blood (2019) 134 (Supplement_1): 5908.

https://doi.org/10.1182/blood-2019-122769

Published: 2019

Journal Articles

Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study

Massimiliano Bonifacio, MD, Mario Tiribelli, Gianni Binotto, MD, Maria Cristina Miggiano, Marco Basso, Elisabetta Calistri, Luigi Scaffidi, MD, Rossella Stella, Luca Frison, Roberto Sartori, Marco Ruggeri, Gianpietro Semenzato, Renato Fanin, Mauro Krampera

Blood (2019) 134 (Supplement_1): 5909.

https://doi.org/10.1182/blood-2019-131272

Published: 2019

Journal Articles

Randomized, Open-Label, Multicenter, Phase 2 Study of Asciminib (ABL001) As an Add-on to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Frontline Imatinib

Giuseppe Saglio, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Jan Geissler, Shruti Kapoor, Anne-Sophie Longin, Ayon Mukherjee, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 5910.

https://doi.org/10.1182/blood-2019-124702

Published: 2019

Journal Articles

Analysis of 48 Cases Pediatric Chronic Myeloid Leukemia from China: Results from a Single Institute in China

Yuli Cai, BS, Chao Liu, MS, Ye Guo, MD, Xiaojuan Chen, MD, Li Zhang, MD, Yumei Chen, MD, Yao Zou, MD, Wenyu Yang, MD, Xiaofan Zhu, MD

Blood (2019) 134 (Supplement_1): 5911.

https://doi.org/10.1182/blood-2019-125565

Published: 2019

Journal Articles

Clinico-Pathological Profiles of Obese Patients with Chronic Myeloid Leukemia (CML) and Their Response to Therapies (TKIs)

Mohamed A Yassin, MBBS, MSc, Mohammad Abdul-Jaber Abdulla, MD, Feryal Abbas, MD PhD, Prem Chandra, PhD, Abdulqadir Jeprel Nashwan, BSN, MSN, Rola S Ghasoub, BSC, Nancy Kassem, BSC, Ahmad Al Sabbagh, MD, Zafar Nawaz, PhD, Susanna Jane Akiki, PhD

Blood (2019) 134 (Supplement_1): 5912.

https://doi.org/10.1182/blood-2019-125700

Published: 2019

Journal Articles

Long Term Response Evaluation of Newly Diagnosed Chronic Myeloid Leukemia Patients on Imatinib Mesylate in Indian Population over 12 Years

Tara Rajendran, MBBS, Prasad Pramod Rane, MPH, Krishna Prasad, MBBS, MD(Internal MDcine), DM (Oncology)

Blood (2019) 134 (Supplement_1): 5913.

https://doi.org/10.1182/blood-2019-125978

Published: 2019

Journal Articles

Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China

Li Zhou, Bingcheng Liu, Jianda Hu, PhD, Jianhua Qu, Ming Hou, MD, Hui Sun, Jie Jin, MD PhD, Zhixiang Shen

Blood (2019) 134 (Supplement_1): 5914.

https://doi.org/10.1182/blood-2019-126546

Published: 2019

Journal Articles

Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

Renato Torrescasana Centrone, Marcelo Bellesso, MD, Rodrigo Santucci Silva, MD, Eliseo J. Sekiya, MD, Milton A. F. Aranha, MD, Isabel Bonafe, Daniela Ferreira Dias, MD, Adelson Alves, MD

Blood (2019) 134 (Supplement_1): 5847.

https://doi.org/10.1182/blood-2019-128629

Published: 2019

Journal Articles

FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim

Ayako Nogami, MD PhD BPharm, Daisuke Watanabe, MD, Keigo Okada, MD, PhD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Toshikage Nagao, MD, PhD, Shuji Tohda, MD, PhD, Osamu Miura, MD, PhD

Blood (2019) 134 (Supplement_1): 1425.

https://doi.org/10.1182/blood-2019-123183

Published: 2019

Journal Articles

Pricing of First and Second Generation Tyrosine Kinase Inhibitors (TKIs) Pre- and Post-Transition of Imatinib to Generic Status

Kelly Kenzik, PhD, Ravi Bhatia, MD, Smita Bhatia, MDMPH

Blood (2019) 134 (Supplement_1): 2140.

https://doi.org/10.1182/blood-2019-123490

Published: 2019

Journal Articles

The Role of the BMP Pathway in Sustaining CML Stem Cells in the Bone Marrow Niche

Caroline Busch, BSc, MSc, Chloe Gulliver, BSc, MSc, Theresa Mulholland, BSc, Michele Zagnoni, BSc, MSc, PhD, Catherine C. Berry, BSc,PhD, Helen Wheadon, BSc, PhD

Blood (2019) 134 (Supplement_1): 3732.

https://doi.org/10.1182/blood-2019-123967

Published: 2019

Journal Articles

Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL)

Shilpa Paul, PharmD, Koji Sasaki, MD, J Michael Savoy, PharmD, Adam Dipippo, PharmD, Nadya Jammal, PharmD, Kayleigh Marx, PharmD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 3810.

https://doi.org/10.1182/blood-2019-130284

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study

Vaccination with Live Attenuated Virus Vaccines in Four Pediatric Patients with CML While on Imatinib Treatment

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Effects of Ramadan Fasting in Patients with Chronic Myeloid Leukemia in Chronic Phase

Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML

Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study

Randomized, Open-Label, Multicenter, Phase 2 Study of Asciminib (ABL001) As an Add-on to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Frontline Imatinib

Analysis of 48 Cases Pediatric Chronic Myeloid Leukemia from China: Results from a Single Institute in China

Clinico-Pathological Profiles of Obese Patients with Chronic Myeloid Leukemia (CML) and Their Response to Therapies (TKIs)

Long Term Response Evaluation of Newly Diagnosed Chronic Myeloid Leukemia Patients on Imatinib Mesylate in Indian Population over 12 Years

Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China

Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim

Pricing of First and Second Generation Tyrosine Kinase Inhibitors (TKIs) Pre- and Post-Transition of Imatinib to Generic Status

The Role of the BMP Pathway in Sustaining CML Stem Cells in the Bone Marrow Niche

Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only